What's new — Neuropathic pain¶
Generated 2026-09-03 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 0 |
| last 2 months | 1 |
| last 3 months | 2 |
| last 6 months | 2 |
| last year | 3 |
| older than a year | 285 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-07-09 | PROSPER: a phase III trial of lecithinized superoxide dismutase to prevent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer — ESMO Gastrointest Oncol ([PMID 42583153](https://pubmed.ncbi.nlm.nih.gov/42583153/){target="_blank" rel="noopener"}) | chemotherapy-and-toxic-neuropathy |
| 2026-07-01 | New insight into RNA biomarkers in neuropathic pain: a clinician-neuroscientist roadmap to translational testing and treatment monitoring a clinical review — Front Pain Res (Lausanne) ([PMID 42534835](https://pubmed.ncbi.nlm.nih.gov/42534835/){target="_blank" rel="noopener"}) | biomarkers |
| 2025-10-01 | Prevalence of neuropathic pain following spinal cord injury: An updated systematic review and meta-analysis — J Clin Neurosci ([PMID 41043376](https://pubmed.ncbi.nlm.nih.gov/41043376/){target="_blank" rel="noopener"}) | epidemiology-and-burden, overview |
Trials — what has moved¶
16 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 1 |
| trial records updated in the last month | 2 |
| trial records updated in the last 2 months | 6 |
| trial records updated in the last 3 months | 6 |
| trial records updated in the last 6 months | 6 |
| trial records updated in the last year | 9 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-07-30 | A Study of LY3556050 in Adult Participants With Diabetic Peripheral Ne | PHASE2 | 404 | Mean Change From Baseline in Average Pain Intensity (API) as Measured | 11 | 71 | 1 |
| 2023-11-22 | Closed-loop Deep Brain Stimulation to Treat Refractory Neuropathic Pai | NA | 4 | Visual Analog Score | 2 | 10 | 0 |
| 2023-09-21 | Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy | PHASE2 | 282 | Change in Mean Average Pain Intensity (NRS) | 12 | 58 | 0 |
| 2011-12-08 | A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain D | PHASE3 | 220 | Duration Adjusted Average Change (DAAC) of Mean Pain Score | 19 | 134 | 0 |
10 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| chemotherapy-and-toxic-neuropathy | 2026-07-09 | 1 | 32 |
| biomarkers | 2026-07-01 | 1 | 31 |
| epidemiology-and-burden | 2025-10-01 | 1 | 29 |
| overview | 2025-10-01 | 1 | 29 |
| neuromodulation | 2025-09-02 | 0 | 30 |
| central-sensitization-and-plasticity | 2025-05-01 | 0 | 29 |
| clinical-trials-landscape | 2025-05-01 | 0 | 28 |
| pharmacologic-treatment | 2025-01-07 | 0 | 34 |
| diabetic-neuropathic-pain | 2024-12-07 | 0 | 30 |
| topical-and-interventional-treatment | 2024-12-02 | 0 | 28 |
| peripheral-mechanisms | 2024-10-08 | 0 | 34 |
| sensory-phenotyping-and-qst | 2024-10-02 | 0 | 30 |
| spinal-cord-and-central-neuropathic-pain | 2024-10-01 | 0 | 31 |
| patient-experience-and-advocacy | 2024-09-03 | 0 | 32 |
| postherpetic-and-postsurgical-pain | 2024-09-03 | 0 | 31 |
| definition-grading-and-diagnosis | 2024-08-05 | 0 | 30 |
| guidelines | 2024-08-05 | 0 | 32 |
| red-flags-and-safety-concerns | 2023-12-02 | 0 | 30 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.